Join Growin Stock Community!

Zimmer biomet holdings, inc.ZBH.US Overview

US StockHealthcare
(No presentation for ZBH)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ZBH AI Insights

ZBH Overall Performance

ZBH AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ZBH Recent Performance

-2.82%

Zimmer biomet holdings, inc.

-3.61%

Avg of Sector

-2.16%

S&P500

ZBH PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ZBH Key Information

ZBH Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

ZBH Profile

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as robotic, surgical and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

Price of ZBH

ZBH FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ZBH Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
3.56
PE Ratio (TTM)
27.73
Forward PE
11.08
PS Ratio (TTM)
2.37
PB Ratio
1.58
Price-to-FCF
16.57
METRIC
VALUE
vs. INDUSTRY
Gross Margin
69.71%
Net Margin
8.56%
Revenue Growth (YoY)
7.20%
Profit Growth (YoY)
4.57%
3-Year Revenue Growth
7.13%
3-Year Profit Growth
3.61%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
3.56
PE Ratio (TTM)
27.73
Forward PE
11.08
PS Ratio (TTM)
2.37
PB Ratio
1.58
Price-to-FCF
16.57
Gross Margin
69.71%
Net Margin
8.56%
Revenue Growth (YoY)
7.20%
Profit Growth (YoY)
4.57%
3-Year Revenue Growth
7.13%
3-Year Profit Growth
3.61%

  • When is ZBH's latest earnings report released?

    The most recent financial report for Zimmer biomet holdings, inc. (ZBH) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ZBH's short-term business performance and financial health. For the latest updates on ZBH's earnings releases, visit this page regularly.

  • Where does ZBH fall in the P/E River chart?

    According to historical valuation range analysis, Zimmer biomet holdings, inc. (ZBH)'s current price-to-earnings (P/E) ratio is 27.4, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of ZBH?

    According to the latest financial report, Zimmer biomet holdings, inc. (ZBH) reported an Operating Profit of 154.5M with an Operating Margin of 6.89% this period, representing a decline of 60.27% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is ZBH's revenue growth?

    In the latest financial report, Zimmer biomet holdings, inc. (ZBH) announced revenue of 2.24B, with a Year-Over-Year growth rate of 10.9%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does ZBH have?

    As of the end of the reporting period, Zimmer biomet holdings, inc. (ZBH) had total debt of 7.52B, with a debt ratio of 0.33. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does ZBH have?

    At the end of the period, Zimmer biomet holdings, inc. (ZBH) held Total Cash and Cash Equivalents of 591.9M, accounting for 0.03 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does ZBH go with three margins increasing?

    In the latest report, Zimmer biomet holdings, inc. (ZBH) achieved the “three margins increasing” benchmark, with a gross margin of 64.7%%, operating margin of 6.89%%, and net margin of 6.2%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess ZBH's profit trajectory and future growth potential.

  • Is ZBH's EPS continuing to grow?

    According to the past four quarterly reports, Zimmer biomet holdings, inc. (ZBH)'s earnings per share (EPS) shows a declining trend, with the latest EPS at 0.71. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ZBH?

    Zimmer biomet holdings, inc. (ZBH)'s Free Cash Flow (FCF) for the period is 368.3M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 133.59% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of ZBH?

    The latest valuation data shows Zimmer biomet holdings, inc. (ZBH) has a Price-To-Earnings (PE) ratio of 27.4 and a Price/Earnings-To-Growth (PEG) ratio of -0.81. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.